Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease

Patients With Alzheimer's Disease Clinical Trial

— PET-SF  

Official title:

Interest of PFS Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease Acquired on a Numerical System

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04718207
• Other study ID #: S201215_051
• Status: Completed
• Start date: February 1, 2021
• Est. completion date: February 1, 2022

Study information

• Verified date: August 2022
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

PET/CT scans with 18F-FDG can be carried out for the detection of neurodegenerative diseases with hypometabolisms characteristic of the pathologies sought. The diagnosis is given by the clinician after a visual analysis of the data. To complete the diagnosis, a semi-quantitative analysis of the images is recommended (European recommendations) in addition to the visual analysis.

Description:

PET/CT scans with 18F-FDG can be carried out for the detection of neurodegenerative diseases with hypometabolisms characteristic of the pathologies sought. The diagnosis is given by the clinician after a visual analysis of the data. To complete the diagnosis, a semi-quantitative analysis of the images is recommended (European recommendations) in addition to the visual analysis.

PET technology is improving from year to year thanks to the arrival of a new PET technology called digital. In addition, correction methods have been developed to improve PET images and thus improve the detection of different pathologies in PET.

The PSF (Point Spread Function) tool enables partial volume effects to be corrected. The PSF consists of correcting the impulse response of the system, and allows a visual improvement of the images. Currently not recommended in brain PET/CT reconstructions, it remains to be evaluated for the quantitative analysis of acquisitions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: February 1, 2022
• Est. primary completion date: August 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Brain PET/CT scans at 18F-FDG of patients with Alzheimer's disease carried out in the nuclear medicine department of the Nancy-Brabois University Hospital since December 2017 on digital PET devices.

Exclusion Criteria:

• Patients who have expressed their opposition to the use of their data (poster in the service).

Related Conditions & MeSH terms

• Alzheimer Disease
• Patients With Alzheimer's Disease

Intervention

Device:
• Brain positron emission tomopgraphy (PET) - scan
Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.

Locations

Country	Name	City	State
France	Nuclear medicine department CHRU de NANCY Brabois	Vandoeuvre les Nancy cedex

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The results obtained in quantitative analysis with and without PSF modelling of PET brain scans of patients with Alzheimer's disease acquired on PET / CT scan	Comparison of the volumes detected by the quantitative analysis with the SPM (statistical parametric Mapping) software of brain PET scans of patients with Alzheimer's disease with and without FSP modelling.	6 months